Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.44
-0.11 (-1.68%)
May 18, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $22.52M in the quarter ending March 31, 2026, with 2.09% growth. This brings the company's revenue in the last twelve months to $117.05M, up 16.30% year-over-year. In the year 2025, Gyre Therapeutics had annual revenue of $116.59M with 10.24% growth.
Revenue (ttm)
$117.05M
Revenue Growth
+16.30%
P/S Ratio
5.03
Revenue / Employee
$187,278
Employees
625
Market Cap
588.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 116.59M | 10.83M | 10.24% |
| Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
| Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
| Dec 31, 2022 | 102.29M | 94.95M | 1,293.98% |
| Dec 31, 2021 | 7.34M | -34.56M | -82.49% |
| Dec 31, 2020 | 41.90M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 6.00K | -1.01M | -99.41% |
| Dec 31, 2017 | 1.02M | 619.00K | 155.14% |
| Dec 31, 2016 | 399.00K | -1.35M | -77.20% |
| Dec 31, 2015 | 1.75M | -63.00K | -3.47% |
| Dec 31, 2014 | 1.81M | 1.29M | 246.65% |
| Dec 31, 2013 | 523.00K | -115.20M | -99.55% |
| Dec 31, 2012 | 115.72M | -79.55M | -40.74% |
| Dec 31, 2011 | 195.27M | 23.85M | 13.91% |
| Dec 31, 2010 | 171.43M | 121.30M | 242.00% |
| Dec 31, 2009 | 50.12M | 9.95M | 24.78% |
| Dec 31, 2008 | 40.17M | 17.02M | 73.51% |
| Dec 31, 2007 | 23.15M | -31.92M | -57.96% |
| Dec 31, 2006 | 55.07M | 52.71M | 2,233.81% |
| Dec 31, 2005 | 2.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| Valneva SE | 180.25M |
| Zevra Therapeutics | 122.29M |
| Sutro Biopharma | 99.61M |
| Arvinas | 89.40M |
| Aclaris Therapeutics | 8.37M |
| Altimmune | 36.00K |
GYRE News
- 6 days ago - Gyre Therapeutics announces China NMPA acceptance of F351 NDA - TheFly
- 6 days ago - Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 11 days ago - Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year - TheFly
- 12 days ago - Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 12 days ago - Gyre Therapeutics Earnings release: Q1 2026 - Filings
- 12 days ago - Gyre Therapeutics Quarterly report: Q1 2026 - Filings
- 14 days ago - Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company - GlobeNewsWire
- 14 days ago - Gyre Therapeutics Proxy statement: Proxy filing - Filings